Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
OptiBiotix Health ( (GB:OPTI) ) has provided an announcement.
OptiBiotix Health has launched its SlimBiome® containing products under the GoFigure® brand on Amazon India, capitalizing on India’s growing market of medium to high-income consumers and a significant obesity prevalence of 40.3%. This strategic move aligns with their multi-channel approach, enhancing visibility and sales through both ecommerce and physical outlets like Apollo Pharmacies. The rebranded packaging and partnership with local manufacturers, incorporating Tata’s Fossence®, aim to increase product appeal and trust among Indian consumers. The launch marks a crucial step in OptiBiotix’s expansion in India, with further product introductions planned for 2025.
More about OptiBiotix Health
OptiBiotix Health plc, established in March 2012, operates in the life sciences industry, focusing on developing compounds to modify the human microbiome for disease prevention and wellness enhancement. The company engages in extensive R&D with leading academics to create microbial strains and compounds, partnering with over twenty international food and healthcare companies. OptiBiotix’s core areas include obesity, cardiovascular health, and diabetes, with an expanding portfolio of consumer supplements and health products.
YTD Price Performance: -5.56%
Average Trading Volume: 470,453
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £16.65M
See more data about OPTI stock on TipRanks’ Stock Analysis page.
